pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,107 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1173Endpoints891BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7585Rare Disease1872Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • STAT+: Color me skeptical: Drinking gold is not an ALS cure
    In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
    STAT · 4mo ago↗ source
  • STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
    The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
    STAT · 4mo ago↗ source
  • STAT+: What was lost at the FDA
    What was lost at the FDA: A year after DOGE’s cuts, six agency staffers describe the work they never thought they’d leave.
    STAT · 4mo ago↗ source
← prev
page 113 of 125
next →
fda recalls69
fda medwatch60
fda press38
1172
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism473
Infectious Disease444
  • Opinion: Eugene Braunwald, ‘father of modern cardiology,’ told me he had two dreams. One came true
    Legendary cardiologist Eugene Braunwald had two visions for his career. One of them came true.
    STAT · 4mo ago↗ source
  • Cruise ship hantavirus outbreak worries experts, though they discount pandemic fears
    Scientists are worried that hantaviruses haven’t been as well studied as they ought to be, but not that the MV Hondius cruise ship is ground zero for the next pandemic.
    STAT · 4mo ago↗ source
  • STAT+: Oregon hospitals won’t outsource to national physician chain after all
    Faced with stiff local opposition and a possible loss in court, PeaceHealth drops plan to replace Eugene Emergency Physicians with staffing chain ApolloMD.
    STAT · 4mo ago↗ source
  • Trump administration’s drug strategy is at odds with recent actions on funding, policy
    The White House nods to medication-assisted treatment and fentanyl test strips, despite recently placing new limits.
    STAT · 4mo ago↗ source
  • Amgen, AbbVie say IRA negotiations impacted Q1 sales
    At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in thei…
    Endpoints · 4mo ago↗ source
  • Lilly plans new $4.5B manufacturing investment in Indiana
    Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects. The world’s largest pharma company, headquarter…
    Endpoints · 4mo ago↗ source
  • BeOne culls five cancer programs and an autoimmune Phase 2
    BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experi…
    Endpoints · 4mo ago↗ source
  • Lonza looks to ride ADC wave with upcoming factory, workforce expansion
    BASEL, Switzerland — Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year and plans to increase its headcount. T…
    Endpoints · 4mo ago↗ source
  • STAT+: Administration report on most favored nation drug pricing raises new details — and questions
    Administration report on most-favored nation drug pricing raises new details — and questions.
    STAT · 4mo ago↗ source
  • STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
    Sanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.
    STAT · 4mo ago↗ source
  • Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
    Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
    Color Health, which coordinates cancer screening, is moving into a gap it observed — obtaining and coordinating actual cancer care.
    STAT · 4mo ago↗ source
  • Novo hikes guidance on Wegovy pill’s fast sales start
    In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.
    BioPharma Dive · 4mo ago↗ source
  • Why the FDA is authorizing fruit-flavored vapes
    Marty Makary says he was "skeptical initially" about flavored vapes but that age-gating technology could limit their use.
    STAT · 4mo ago↗ source
  • Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
    🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, accord…
    Endpoints · 4mo ago↗ source
  • Former Orbital scientists launch new mRNA therapy startup
    Two scientists think they've solved a technical problem that has kept the mRNA revolution from reaching its full potential. Now, they're launching ParcelBio with $13 million in seed funding to deve…
    Endpoints · 4mo ago↗ source
  • Avalo scores Phase 2 success in comeback bid, raises $375M
    Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an experim…
    Endpoints · 4mo ago↗ source
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 4mo ago↗ source
  • Avalo shares spike on skin drug data; BioNTech to cut staff
    Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: When the path to good AI is littered with bad data
    In this edition of AI Prognosis, Brittany Trang raises the question: What kind of health data would we need to train AI models to be useful in health care.
    STAT · 4mo ago↗ source
  • GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
    GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suzho…
    Endpoints · 4mo ago↗ source
  • STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
    Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
    STAT · 4mo ago↗ source